Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
– Cash runway extended through the second quarter of 2026 – – $352 million in cash, cash equivalents and marketable...
Clinical Trial
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals
EMERYVILLE, Calif. and NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and Eyenovia, Inc....
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of...
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee
-- PCRX-201 is the first gene therapy product candidate to receive RMAT designation for osteoarthritis -- -- Designation supported by...
Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer
LEXINGTON, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic...
BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership
Partnership targets heart failure, the leading cause of death and a condition with limited treatment optionsBioCardia’s biotherapeutic delivery system with...
Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments
An ongoing phase 3 clinical trial of SGT-610 for Gorlin Syndrome with the first patient screened; Results are expected by...
ProQR Announces Year End 2023 Operating and Financial Results
Preclinical and translational pipeline program data for AX-0810 for Cholestatic Diseases targeting NTCP and AX-1412 for Cardiovascular Disease targeting B4GALT1...
ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
ZYNLONTA® (loncastuximab tesirine-lpyl) net sales of $16.6 million in 4Q 2023 and $69.1 million for full year (FY) 2023; 4Q...
Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025
STAFFORD, Texas, March 13, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused...
Kuros Reports 163% Growth in Direct MagnetOs Sales and 153% Increase in Total Medical Device Sales for the Full Year 2023
Financial highlightsDirect MagnetOs sales grew by 163% to CHF 31.7 million in 2023, climbing from CHF 12.1 million in 2022....
KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat
– Full EAMS designation would allow treatment of patients with sebetralstat prior to receiving a Marketing Authorization from UK –CAMBRIDGE,...
Gilead Science Supports Increasing Diversity in Clinical Trials: 2024 Toward Health Equity Oncology Grant Supports 36 Global Organizations
NORTHAMPTON, MA / ACCESSWIRE / March 12, 2024 / We're committed to increasing diverse representation in clinical trials, especially for...
CenExel Named Finalist for ‘Best Clinical Trial Company’ at World Vaccine Congress ViE Awards
SALT LAKE CITY, UT / ACCESSWIRE / March 12, 2024 / CenExel, a leading clinical research site network with 18...
Zomedica Announces Sponsorship of Educational Presentations at Fetch dvm360 Veterinary Conferences
ANN ARBOR, MI / ACCESSWIRE / March 12, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary...
Helius Medical Technologies, Inc. Initiates Open-Label Study for Registrational Program in Stroke
-- Enrollment of at least ten patients at Brooks Rehabilitation will begin this month ---- Study will evaluate the use...
Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity
Data provides first demonstration of glucose lowering and weight loss potency from pancreas-produced native human GLP-1, highlighting the capacity of...
Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights
– Topline data from ongoing Phase 1/2 trials of INZ-701 in adults with ABCC6 Deficiency and ENPP1 Deficiency expected in...
Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease
Allogene’s AlloCAR T™ Autoimmune Disease Platform Leverages Arbor’s CRISPR Gene-Editing TechnologyFirst Allogeneic CAR T Phase 1 Clinical Trial in Autoimmune...
SeaStar Medical Provides Updates on Enrollment of Adult Pivotal Clinical Study and Commercial Launch of Quelimmune, FDA-Approved in Pediatric Patients
Company plans to hold a business update conference call in April DENVER, March 12, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical...